Related Experiment Video

Updated: Jul 11, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

17.7K

Molecular targets and therapeutic strategies for triple-negative breast cancer

Yashasvi Bhat1, M R Thrishna1, Satarupa Banerjee2

  • 1School of Bio Science and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, 632014, India.

Molecular Biology Reports
|November 4, 2023
PubMed

Insights

Triple-negative breast cancer (TNBC) and quadruple-negative breast cancer (QNBC) are hard to treat due to limited biomarkers. This review explores novel therapeutic strategies including nutraceuticals and drug repurposing for TNBC.

Area of Science:

  • Oncology
  • Biochemistry
  • Nanomedicine

Background:

  • Triple-negative breast cancer (TNBC) is a complex and challenging malignancy lacking key hormonal receptors.
  • TNBC is subdivided into androgen receptor (AR) positive and AR negative (quadruple-negative breast cancer, QNBC) subtypes.
  • QNBC presents a significant deficit in prognostic biomarkers and therapeutic targets, characterized by excessive tumor cell proliferation.

Purpose of the Study:

  • To review existing protein biomarkers for TNBC and QNBC molecular targeting.
  • To highlight recent advancements in therapeutic strategies for TNBC treatment.
  • To explore novel approaches including nutraceuticals, drug repurposing, and nanomedicines.

Main Methods:

  • Literature review of protein biomarkers in TNBC and QNBC.
  • Analysis of current targeted therapy and immune checkpoint inhibitor applications.
  • Examination of drug repurposing, nutraceuticals, functional foods, and nanomedicine research.

Main Results:

  • Limited protein biomarker data exists for QNBC, necessitating further research.
  • Novel compounds are actively being synthesized for antiproliferative effects against TNBC.
  • Nutraceuticals, drug repositioning, and nanomedicines show promise as therapeutic avenues.

Conclusions:

  • There is a critical need for identifying new biomarkers and therapeutic targets for QNBC.
  • Drug repurposing and nutraceuticals offer potential alternative or complementary treatments for TNBC.
  • Nanomedicine presents innovative strategies for cancer treatment, including TNBC.
Keywords:
Antiproliferative medicinesProtein biomarkersQuadruple-negative breast cancerTargeted therapyTriple-negative breast cancer

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K